Zacks Research Has Optimistic Outlook of TEVA Q2 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research boosted their Q2 2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.62 for the quarter, up from their prior forecast of $0.61. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2026 earnings at $0.68 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the previous year, the business earned $0.48 EPS. Teva Pharmaceutical Industries's revenue for the quarter was up 1.9% compared to the same quarter last year.

TEVA has been the subject of a number of other reports. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday. They issued a "buy" rating and a $25.00 price target for the company. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and an average price target of $24.50.

Teva Pharmaceutical Industries Stock Down 4.3%

TEVA stock traded down $0.76 during midday trading on Friday, hitting $16.77. 19,852,269 shares of the company's stock were exchanged, compared to its average volume of 10,105,614. The stock has a market capitalization of $19.01 billion, a price-to-earnings ratio of -11.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The firm has a 50 day moving average price of $15.52 and a 200-day moving average price of $17.37. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC increased its holdings in Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Fifth Third Bancorp boosted its position in Teva Pharmaceutical Industries by 6,682.6% during the fourth quarter. Fifth Third Bancorp now owns 18,720 shares of the company's stock valued at $413,000 after purchasing an additional 18,444 shares during the last quarter. Blue Trust Inc. boosted its position in Teva Pharmaceutical Industries by 42.3% during the fourth quarter. Blue Trust Inc. now owns 20,809 shares of the company's stock valued at $459,000 after purchasing an additional 6,190 shares during the last quarter. KBC Group NV boosted its stake in shares of Teva Pharmaceutical Industries by 43.2% during the 4th quarter. KBC Group NV now owns 37,163 shares of the company's stock worth $819,000 after acquiring an additional 11,220 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after acquiring an additional 33,277 shares during the period. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.